Roche: new class of flu medicine shows benefit
(CercleFinance.com) - A phase III study has showed that Roche's antiviral baloxavir marboxil reduced symptoms in people at high risk of complications from flu, the Swiss drugmaker said on Tuesday.
The investigational oral, single-dose flu medicine with a novel proposed mechanism of action has demonstrated "significant efficacy" in high-risk patients, Roche said.
Influenza represents annually between 3 and 5 million cases of severe disease, millions of hospitalisations and up to 650,000 deaths worldwide.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The investigational oral, single-dose flu medicine with a novel proposed mechanism of action has demonstrated "significant efficacy" in high-risk patients, Roche said.
Influenza represents annually between 3 and 5 million cases of severe disease, millions of hospitalisations and up to 650,000 deaths worldwide.
Copyright (c) 2018 CercleFinance.com. All rights reserved.